Literature DB >> 16899498

Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease.

K P Machold1, T A Stamm, V P K Nell, S Pflugbeil, D Aletaha, G Steiner, M Uffmann, J S Smolen.   

Abstract

OBJECTIVES: Despite early recognition and disease modifying anti-rheumatic drug (DMARD) treatment, a sizable proportion of early rheumatoid arthritis (RA) patients show radiological progression. This study was performed to determine the frequency of erosive arthritis and the pace of radiological progression in an inception cohort of patients with very early RA (<or=3 months after onset of symptoms).
METHODS: In order to determine possible prognostic factors for development of erosive disease, we linked the clinical features of these patients to radiological progression in a regression model. About 55 patients with RA and follow-up of at least 3 yrs were analysed. All had complete series of clinical, serological and radiographic assessments. Radiographs were scored according to the Larsen method.
RESULTS: Erosive disease developed in 63.6% of the patients over 3 yrs, with the majority (74.3%) appearing already in the first and 97.2% by the end of the second year. Among all variables available, rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) first presentation were the most predictive for both development of erosions and the degree of radiological progression. None of the clinical variables at the onset was useful to discriminate between erosive and non-erosive patients. In the final regression model, however, cumulative clinical activity substantially contributed to explaining radiological progression.
CONCLUSION: Despite early treatment, substantial damage occurred in some patients and was associated with presence of strong 'constitutive' predictors such as anti-CCP and RF as well as presence of high long-term clinical disease activity as indicated by C-reactive protein (CRP), swollen joint counts and the absence of a good clinical response (assessed by the failure to achieve lasting low disease activity).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16899498     DOI: 10.1093/rheumatology/kel237

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  97 in total

Review 1.  Skeletal complications of rheumatoid arthritis.

Authors:  L Heinlen; M B Humphrey
Journal:  Osteoporos Int       Date:  2017-08-04       Impact factor: 4.507

2.  A bone to pick with Fc gamma receptors.

Authors:  Christian M Karsten; Jörg Köhl
Journal:  Ann Transl Med       Date:  2015-09

Review 3.  Antibodies to citrullinated proteins: pathogenic and diagnostic significance.

Authors:  V Michael Holers
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

Review 4.  Oxidative Modifications in Tissue Pathology and Autoimmune Disease.

Authors:  Mei-Ling Yang; Hester A Doyle; Steven G Clarke; Kevan C Herold; Mark J Mamula
Journal:  Antioxid Redox Signal       Date:  2017-12-11       Impact factor: 8.401

Review 5.  Genetic markers as therapeutic target in rheumatoid arthritis: A game changer in clinical therapy?

Authors:  A M Mohamed Thoufic Ali; S Vino
Journal:  Rheumatol Int       Date:  2016-09-16       Impact factor: 2.631

6.  [Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)].

Authors:  Klaus P Machold; Hans Peter Brezinsek; Burkhard F Leeb; Stephan Pflugbeil; Franz Rainer; Franz Singer; Martin Skoumal; Tanja A Stamm; Manfred Herold
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 7.  Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.

Authors:  Rohit Aggarwal; Katherine Liao; Raj Nair; Sarah Ringold; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-11-15

Review 8.  Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Authors:  Emilio Martin-Mola; Alejandro Balsa; Rosario García-Vicuna; Juan Gómez-Reino; Miguel Angel González-Gay; Raimon Sanmartí; Estíbaliz Loza
Journal:  Rheumatol Int       Date:  2016-06-06       Impact factor: 2.631

9.  The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis.

Authors:  R B Mueller; M Schiff; T Kaegi; A Finckh; S R Haile; H Schulze-Koops; J von Kempis
Journal:  Clin Rheumatol       Date:  2014-07-15       Impact factor: 2.980

10.  Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study.

Authors:  Benedicte A Lie; Marte K Viken; Sigrid Odegård; Désirée van der Heijde; Robert Landewé; Till Uhlig; Tore K Kvien
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.